Access to biologic therapies in Canada for children with juvenile idiopathic arthritis.
Leblanc CM, Lang B, Bencivenga A, Chetaille AL, Dancey P, Dent P, Miettunen P, Oen K, Rosenberg A, Roth J, Scuccimarri R, Tse SM, Benseler S, Cabral DA, Campillo S, Chédeville G, Duffy CM, Duffy KW, Haddad E, Huber AM, Laxer R, Levy D, Johnson N, Ramsey S, Shiff N, Schmeling H, Schneider R, Stringer E, Yeung RS, Tucker LB.
Leblanc CM, et al.
J Rheumatol. 2012 Sep;39(9):1875-9. doi: 10.3899/jrheum.120089. Epub 2012 Aug 1.
J Rheumatol. 2012.
PMID: 22859344
There is urgent need for public policy to improve access to biologic therapies for these children to ensure optimal short-term and longterm health outcomes....
There is urgent need for public policy to improve access to biologic therapies for these children to ensure optimal short-term and lo …